Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Amarin Corporation Plc

Bristol-Myers

Blackstone Group

Clovis Oncology

Journey Medical Corp

Johnson & Johnson

Kaleido Biosciences Inc

Eli Lilly

Medtronic

Roche Holding AG

Sanofi

Sorrento Therapeutics Inc

The Super Bowl of healthcare kicked off early for these companies.

All the 2020 Pre-JPM News Healthcare Investors Need to Know

DexCom

Insulet

Vertex Pharmaceuticals

Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference.

Vertex, Dexcom, Insulet, Intuitive Surgical In Buy Range Before Healthcare Conference

Amazon

Livongo Health Inc

Pinterest

These high-growth businesses should have you seeing dollar signs.

5 Top Growth Stocks You'll Want to Own in 2020

Revenue increased by 22% to $1.28 billion.

Intuitive Surgical Reports Preliminary Fourth Quarter 2019 Results

KB Home

NortonLifeLock

Moderna

Portola Pharmaceuticals

Take a look at the companies making headlines after the bell.

Stocks making the biggest moves after the bell: KB Home, Intuitive Surgical, NortonLifeLock and more

Accuray

Which stock is the better option for investors looking to profit from the market for medical devices?

Better Buy: Intuitive Surgical vs. Accuray

Guardant Health Inc

Here are three compelling reasons to buy healthcare stocks this year.

Why Your 2020 Resolution Should Be to Buy More Healthcare Stocks

Abbott Labs

Shockwave Medical

These medical device stocks should be poised for a happy new year.

3 Top Medical Device Stocks to Buy in January

Exelixis

Innovative Industrial Properties

NextEra Energy

SSR Mining

Visa

Start the year off right by investing in these top-tier companies.

10 Top Stocks That Will Make You Richer in 2020

Alexion Pharma

Qorvo

Block

These large-cap growth and value stocks could make you richer this year.

4 No-Brainer Large-Cap Stocks to Own in 2020

Axsome Therapeutics

Three very different areas of healthcare. One big common denominator: great growth prospects.

3 Top Healthcare Stocks to Buy in January

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.

Here's Why You Should Hold on to Intuitive Surgical for Now

These three healthcare stocks have all the ingredients needed to cook up great returns in the new year.

The 3 Best Healthcare Stocks to Buy for 2020

Apple

Disney

If you have a long-term focus, these companies could deliver market-beating returns for decades.

3 Stocks  to Hold for the Next 20 Years

Costco

Alphabet

Lennox International

Sherwin-Williams

SVB Financial Group

Forget $10 stocks to buy. Instead, why not look for stocks to buy that are priced at $250 and beyond?

7 Impressive Stocks to Buy Over $250

These two companies are industry leaders in their respective fields.

2 Healthcare Stocks I’d Buy Right Now

Which stock wins in a matchup between these two medical device leaders?

Better Buy:  Intuitive Surgical vs.  Medtronic

Stryker

With minimally invasive surgery gaining momentum, these stocks are poised to capitalize on the market prospects.

Minimally Invasive Surgery Gains Ground: 3 Stocks in Focus

ISRG stock climbed 20% in 2019 as of mid-December. But Intuitive Surgical stock’s performance lagged other medical technology stocks.

ISRG Stock: Should You Invest In This Robotic Surgery Giant?

McCormick

Waste Management

With a record amount of cash on hand, the Oracle of Omaha should go shopping.

3 Stocks Warren Buffett Should Buy Right Now

A holding period of forever sounds perfect for these top-tier businesses.

3 Healthcare Stocks to Buy and Never Sell

Teladoc

They dominate their respective markets. And they have fantastic growth prospects.

3 Top Healthcare Stocks to Buy in December

CoStar Group

Shopify

The financial strength criterion of Benjamin Graham, the father of value investing, tells that if investors go for stocks whose current ratio exceeds 2 and which have more working capital than long-term debt, their search will likely uncover high-quality companies to add to their portfolios.

3 High Quality Stocks for the Value Investor: CSGP, ISRG & SHOP

Though the stock market offers no guarantees, the pendulum appears to heavily favor long-term investors profiting from this dominant company.

This Stock Is the Closest Thing to a Surefire Investment

Intuitive Surgical’s (NASDAQ: ISRG) research and development (R&D) expenses jumped 2x from $197 million in 2015 to $418 million in 2018, due to its new devices development initiatives, including da Vinci Single Port Surgical System and robotic-assisted catheter-based medical devices.

News for Intuitive Surgical Stock (ISRG)